Filgrastim (r-metHuG-CSF): the first 10 years.
Welte
K
K
Medizinische Hochschule, Hannover, Germany.
Gabrilove
J
J
Bronchud
M H
MH
Platzer
E
E
Morstyn
G
G
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D000741:Anemia, Aplastic / Q000188:drug therapy; D000818:Animals; D002986:Clinical Trials as Topic; D003365:Costs and Cost Analysis; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor; D006410:Hematopoiesis; D006801:Humans; D000078224:Lenograstim; D008223:Lymphoma / Q000188:drug therapy; D051379:Mice; D008958:Models, Molecular; D009190:Myelodysplastic Syndromes / Q000188:drug therapy; D009503:Neutropenia / Q000188:drug therapy*; D011788:Quality of Life; D011994:Recombinant Proteins / Q000627:therapeutic use; D016019:Survival Analysis
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000078224:Lenograstim; D000069585:Filgrastim